Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice
- PMID: 12915461
- DOI: 10.1093/hmg/ddg267
Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice
Abstract
The glial glutamate transporter EAAT2 is primarily responsible for clearance of glutamate from the synaptic cleft and loss of EAAT2 has been previously reported in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The loss of functional EAAT2 could lead to the accumulation of extracellular glutamate, resulting in cell death known as excitotoxicity. However, it is still unknown whether it is a primary cause in the cascade leading to neuron degeneration or a secondary event to cell death. The goals of this study were to generate transgenic mice overexpressing EAAT2 and then to cross these mice with the ALS-associated mutant SOD1(G93A) mice to investigate whether supplementation of the loss of EAAT2 would delay or rescue the disease progression. We show that the amount of EAAT2 protein and the associated Na+-dependent glutamate uptake was increased about 2-fold in our EAAT2 transgenic mice. The transgenic EAAT2 protein was properly localized to the cell surface on the plasma membrane. Increased EAAT2 expression protects neurons from L-glutamate induced cytotoxicity and cell death in vitro. Furthermore, our EAAT2/G93A double transgenic mice showed a statistically significant (14 days) delay in grip strength decline but not in the onset of paralysis, body weight decline or life span when compared with G93A littermates. Moreover, a delay in the loss of motor neurons and their axonal morphologies as well as other events including caspase-3 activation and SOD1 aggregation were also observed. These results suggest that the loss of EAAT2 may contribute to, but does not cause, motor neuron degeneration in ALS.
Similar articles
-
Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS.Exp Neurol. 2017 Jun;292:145-153. doi: 10.1016/j.expneurol.2017.03.014. Epub 2017 Mar 22. Exp Neurol. 2017. PMID: 28342750 Free PMC article.
-
Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.Neurobiol Dis. 2014 Apr;64:48-59. doi: 10.1016/j.nbd.2013.11.006. Epub 2013 Dec 19. Neurobiol Dis. 2014. PMID: 24361555
-
GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.Neurobiol Dis. 2015 Jun;78:12-23. doi: 10.1016/j.nbd.2015.03.010. Epub 2015 Mar 25. Neurobiol Dis. 2015. PMID: 25818008
-
Excitotoxicity in ALS: Overstimulation, or overreaction?Exp Neurol. 2016 Jan;275 Pt 1:162-71. doi: 10.1016/j.expneurol.2015.09.019. Epub 2015 Nov 13. Exp Neurol. 2016. PMID: 26584004 Review.
-
[Superoxide dismutase-1 (SOD-1) gene mutation-dependent mechanisms of neural degeneration in amyotrophic lateral sclerosis].Neurol Neurochir Pol. 2001 Mar-Apr;35(3):461-9. Neurol Neurochir Pol. 2001. PMID: 11732268 Review. Polish.
Cited by
-
The m6A reader YTHDC2 promotes the pathophysiology of temporal lobe epilepsy by modulating SLC7A11-dependent glutamate dysregulation in astrocytes.Theranostics. 2024 Sep 3;14(14):5551-5570. doi: 10.7150/thno.100703. eCollection 2024. Theranostics. 2024. PMID: 39310099 Free PMC article.
-
Common and Divergent Mechanisms in Developmental Neuronal Remodeling and Dying Back Neurodegeneration.Curr Biol. 2016 Jul 11;26(13):R628-R639. doi: 10.1016/j.cub.2016.05.025. Curr Biol. 2016. PMID: 27404258 Free PMC article. Review.
-
Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS.J Clin Invest. 2020 Mar 2;130(3):1139-1155. doi: 10.1172/JCI130988. J Clin Invest. 2020. PMID: 31714900 Free PMC article.
-
Time-course and characterization of orolingual motor deficits in B6SJL-Tg(SOD1-G93A)1Gur/J mice.Neuroscience. 2008 Jan 24;151(2):613-21. doi: 10.1016/j.neuroscience.2007.10.017. Epub 2007 Oct 30. Neuroscience. 2008. PMID: 18061359 Free PMC article.
-
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.Int J Mol Sci. 2020 Apr 16;21(8):2775. doi: 10.3390/ijms21082775. Int J Mol Sci. 2020. PMID: 32316335 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous